The company claims that Crown PRT is the latest advancement in stented aortic bioprosthesis technology, featuring surgeon-friendly design, PRT technology, hemodynamic and durability performance.
The new stented aortic bioprosthesis enables intraoperative handling through short rinse time, enhanced ease of implant through visible markers, as well as improved radiographic visualization through dedicated X-ray markers.
According to Sorin, research has demonstrated that phospholipids play a key role in the calcification process of bioprotheses and the company’s phospholipid reduction treatment (PRT) has been shown to decrease phospholipid content in pericardial tissue thus leading to a remarkable reduction of calcium uptake compared to control.
Sorin Cardiac Surgery business unit president Michel Darnaud said: "Crown PRT promises to further advance our presence in tissue valve segments in Europe and globally.
"This new innovation for heart valve replacement is strategically designed to provide physicians with greater surgical versatility as well as outstanding durability, reinforcing Sorin’s brand promise to deliver industry-leading technologies in cardiac surgery."
Image: Sorin Group’s Crown PRT heart valve. Photo: Courtesy of Business Wire
